

EMIF Deliverable 16.14: Interim Assessment of the Project

Executive summary

Executive Summary

In this deliverable, an interim assessment of the project was performed to evaluate overall progress so far and identify any challenges or issues potentially impacting the achievement of the envisaged goals and/or deliverables.

This exercise was conducted in the summer of 2015 by the EMIF-PMO, with Work Package (WP) mini-reports collected for all WPs, in parallel with an overall update of the EMIF Dissemination and Risk Trackers. A fixed structure for input collection was used to maximally obtain comparable inputs and limit the efforts required from WP Leaders to complete this report as much as possible. Also, since the structure was mainly based on the type of inputs required for the annual reporting to the IMI Office, the content generated was maximally re-usable.

The results showed that at mid-point, the project is largely progressing as planned with besides clear highlights for all Work Packages, also some challenges/issues to be tackled to assure timely achievement of goals and deliverables.

In terms of dissemination activities, the project seems to be getting up to full speed, with 23 presentations, 6 posters and 14 publications reported in the first half of 2015, with many more planned and/or in preparation.

For the risk management, multiple risks were updated in the first half of 2015 to either change the risk scores (impact and/or probability) or update the mitigation and or contingency plans. In addition, some of the originally identified risks have been 'managed out', as these are considered no longer relevant/applicable to the project, or mitigation plans have been implemented so that the risk as such is no longer a risk, but rather has become an issue.

All results have been shared with the project leader teams, and appropriate follow up actions have been defined. In addition, this report will serve as an important input to the third periodic reporting and the Mid Term Review meeting that will be held in April 2016.

Contacts

EMIF-PMO: Caroline Sage <u>csage@its.jnj.com</u>







This work has received support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking (EMIF grant n° 115372). © Copyright 2015 EMIF Consortium

1